The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells

Paola Storti, Denise Toscani, Irma Airoldi, Valentina Marchica, Sophie Maiga, Marina Bolzoni, Elena Fiorini, Nicoletta Campanini, Eugenia Martella, Cristina Mancini, Daniela Guasco, Valentina Ferri, Gaetano Donofrio, Franco Aversa, Martine Amiot, Nicola Giuliani

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)e107-e110
JournalHaematologica
Volume101
Issue number3
DOIs
Publication statusPublished - 2016

Keywords

  • Hypoxia inducible factor (HIF)-1α suppression
  • In vivo
  • Lenalidomide sensitivity
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology

Cite this

Storti, P., Toscani, D., Airoldi, I., Marchica, V., Maiga, S., Bolzoni, M., Fiorini, E., Campanini, N., Martella, E., Mancini, C., Guasco, D., Ferri, V., Donofrio, G., Aversa, F., Amiot, M., & Giuliani, N. (2016). The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells. Haematologica, 101(3), e107-e110. https://doi.org/10.3324/haematol.2015.133736